Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis
NCT ID: NCT04413942
Last Updated: 2022-04-04
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2
Total Enrollment
99 participants
Study Classification
INTERVENTIONAL
Study Start Date
2020-03-10
Study Completion Date
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study aims to evaluate the efficacy, improvement from baseline in Eczema Area and Severity Index (EASI) score, of multiple intravenous (IV) doses of FB825 in subjects with atopic dermatitis
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT06397911
Atopic Dermatitis
RECRUITING
PHASE2
Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis
NCT05059509
Atopic Dermatitis
COMPLETED
PHASE2
Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis
NCT04504279
Atopic Dermatitis
COMPLETED
PHASE2
Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
NCT04893941
Moderate-to-severe Atopic Dermatitis
COMPLETED
PHASE1/PHASE2
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
NCT06144424
Atopic Dermatitis
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
IgE plays an important role in mediating hypersensitivity reactions responsible for most of the allergic diseases, such as atopic dermatitis, asthma etc. which remain poorly controlled. FB825 blocks the biological pathway of IgE synthesis and thus can be used to treat IgE-mediated allergic diseases.
FB825 was found to be safe when given IV repeat dose in toxicology study in monkey. No adverse effects of FB825 were observed in parameters included electrocardiograms for cardiovascular, ophthalmic examinations and other clinical, CNS and respiratory safety observations.
The safety and tolerability of FB825 was demonstrated in the US phase I randomized, double-blind study with healthy subjects. Also, the FB825 was proved by in vivo study that it is able to block the biological pathway of IgE synthesis and thus can be used to treat IgE-mediated allergic diseases. Therefore, in this study, the effects of IgE in patients with atopic dermatitis receiving FB825 treatment will be investigated. The study will evaluate safety and efficacy in adults with atopic dermatitis.
FB825 was found to be safe when given IV repeat dose in toxicology study in monkey. No adverse effects of FB825 were observed in parameters included electrocardiograms for cardiovascular, ophthalmic examinations and other clinical, CNS and respiratory safety observations.
The safety and tolerability of FB825 was demonstrated in the US phase I randomized, double-blind study with healthy subjects. Also, the FB825 was proved by in vivo study that it is able to block the biological pathway of IgE synthesis and thus can be used to treat IgE-mediated allergic diseases. Therefore, in this study, the effects of IgE in patients with atopic dermatitis receiving FB825 treatment will be investigated. The study will evaluate safety and efficacy in adults with atopic dermatitis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Atopic Dermatitis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Arm A: FB825 Arm B: Placebo
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FB825
FB825
Group Type
ACTIVE_COMPARATOR
FB825
Intervention Type
BIOLOGICAL
Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE
Placebo
Formulation buffer
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
Formulation buffer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FB825
Humanized monoclonal IgG1 specifically targeting the CεmX domain of membrane-bound IgE
Intervention Type
BIOLOGICAL
Placebo
Formulation buffer
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The subject is male or female between 18 and 70 years of age.
2. The subject has a physician-confirmed diagnosis of chronic atopic dermatitis based on 2 years history of symptoms defined by the Eichenfield revised criteria of Hannifin and Rajka.
3. Eczema Area and Severity Index (EASI) score ≧16 at the screening and baseline (Day 1) visits.
4. Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) score ≧ 3 (5-point scale) at the screening and baseline (Day 1) visits.
5. ≧10 % body surface area (BSA) of AD involvement at the screening and baseline (Day 1) visits.
Note: BSA is measured as Part A (Extent) of SCORAD.
6. Baseline pruritus numerical rating scale (NRS) average score for maximum itch intensity of ≧3, based on the average of daily pruritus NRS scores for maximum itch intensity reported during the 7 days prior to randomization.
7. History of inadequate response to a stable (4 weeks) regimen of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) as treatment for AD within 6 months before the screening visit. (The regimen of topical corticosteroids means medium to higher potency, applied for at least 4 weeks or for the maximum duration recommended by product prescribing information.) 7.1 Inadequate response is defined as failure to achieve and maintain remission or a low disease activity state (comparable to vIGA-AD 0=clear to 2=mild) 7.2 Subjects with systemic treatment for AD in the past 6 months were also considered as inadequate responders to topical treatments and were potentially eligible for treatment with FB825 after appropriate washout.
8. Patients must be applying stable doses of an additive-free, basic bland emollient twice-daily for at least 1 week immediately before the baseline visit (Day 1).
Note: See exclusion criterion #11 for limitations regarding emollients
9. Female subjects of childbearing potential must use an acceptable method of birth control (i.e., diaphragm, intrauterine device, condom, hormonal contraceptives, or abstinence) throughout the study or be surgically sterile (i.e., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or postmenopausal (defined as amenorrhea 12 consecutive months and documented serum follicle stimulating hormone level \>40 mU/mL). All female subjects must have a negative serum pregnancy test at screening and baseline (Day 1) visits.
Note: The subject must use the method of effective contraception during study period and in 16 weeks or 5 half-lives after the last dosing of FB825.
10. The subject is able to provide written informed consent.
11. The subject agrees to comply with all protocol requirements.
2. The subject has a physician-confirmed diagnosis of chronic atopic dermatitis based on 2 years history of symptoms defined by the Eichenfield revised criteria of Hannifin and Rajka.
3. Eczema Area and Severity Index (EASI) score ≧16 at the screening and baseline (Day 1) visits.
4. Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) score ≧ 3 (5-point scale) at the screening and baseline (Day 1) visits.
5. ≧10 % body surface area (BSA) of AD involvement at the screening and baseline (Day 1) visits.
Note: BSA is measured as Part A (Extent) of SCORAD.
6. Baseline pruritus numerical rating scale (NRS) average score for maximum itch intensity of ≧3, based on the average of daily pruritus NRS scores for maximum itch intensity reported during the 7 days prior to randomization.
7. History of inadequate response to a stable (4 weeks) regimen of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) as treatment for AD within 6 months before the screening visit. (The regimen of topical corticosteroids means medium to higher potency, applied for at least 4 weeks or for the maximum duration recommended by product prescribing information.) 7.1 Inadequate response is defined as failure to achieve and maintain remission or a low disease activity state (comparable to vIGA-AD 0=clear to 2=mild) 7.2 Subjects with systemic treatment for AD in the past 6 months were also considered as inadequate responders to topical treatments and were potentially eligible for treatment with FB825 after appropriate washout.
8. Patients must be applying stable doses of an additive-free, basic bland emollient twice-daily for at least 1 week immediately before the baseline visit (Day 1).
Note: See exclusion criterion #11 for limitations regarding emollients
9. Female subjects of childbearing potential must use an acceptable method of birth control (i.e., diaphragm, intrauterine device, condom, hormonal contraceptives, or abstinence) throughout the study or be surgically sterile (i.e., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or postmenopausal (defined as amenorrhea 12 consecutive months and documented serum follicle stimulating hormone level \>40 mU/mL). All female subjects must have a negative serum pregnancy test at screening and baseline (Day 1) visits.
Note: The subject must use the method of effective contraception during study period and in 16 weeks or 5 half-lives after the last dosing of FB825.
10. The subject is able to provide written informed consent.
11. The subject agrees to comply with all protocol requirements.
Exclusion Criteria
1. Female subjects who are pregnant or lactating.
2. The subject has a positive test result for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus antibody, or human immunodeficiency virus antibodies at screening. Having a history of human immunodeficiency virus (HIV) infection.
3. The subject has a history of drug abuse that would impair or risk the patients' full participation in the study, in the opinion of the investigator.
4. The subject has a clinically significant, currently active or underlying gastrointestinal, cardiovascular, nervous system, psychiatric, metabolic, renal, hepatic, respiratory (with the exception of uncomplicated allergic rhinitis), inflammatory, immunological, endocrine, diabetes, or infectious disease and is ineligible to participate in the study as judged by the investigator.
5. The subject has a clinically significant history, as determined by the investigator, of drug allergies or hypersensitivity such as, but not limited to, sulfonamides and penicillin, or a drug allergy witnessed in a previous study with experimental drugs.
6. The subject has any history of a previous anaphylactic reaction.
7. The subject has any condition that, in the opinion of the investigator, would compromise the study or the well-being of the subject or prevent the subject from meeting or performing study requirements.
8. The subject has received TCS or TCI within 7 days before the baseline visit (Day 1).
9. The subject has received any immunoglobulin products or blood products within 3 months of baseline visit (Day 1).
10. The subject has received a biologic product (including investigational biologic product):
10.1 Any cell-depleting agents, not only limited to rituximab, within 6 months of baseline visit (Day 1), or before the lymphocyte count returns to normal, whichever is longer.
10.2 Other biologics such as dupilumab within 5 half-lives (if known) or within 16 weeks, whichever is longer, before the study treatment.
11. Initiation of treatment of AD with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period (patients may continue using stable doses of such moisturizers if initiated before the screening visit)
12. The subject has received an investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer, before study treatment.
13. The subject is a member of the professional or ancillary personnel involved in the study.
14. The subject regular use (≧2 visits per week) of a tanning booth/parlor within 4 weeks of the baseline visit (Day 1).
15. The subject has received any immunotherapy treatment within 3 months of baseline visit (Day 1).
16. The subject has used any of the following classes of medication (prescription or over the counter):
16.1 Systemic corticosteroids within 4 weeks before the study treatment 16.2 Leukotriene modifiers within 4 weeks before the study treatment 16.3 Cyclosporine within 12 weeks before the study treatment, or other immunosuppressants (e.g. gold salts, methotrexate, azathioprine) within 4 weeks before the study treatment 16.4 IFN-gamma within 12 weeks before the study treatment, or other immunomodulating drugs within 4 weeks before the study treatment 16.5 Anti-IgE (e.g., omalizumab) within 1 year before the study treatment 16.6 Allergen immunotherapy within 1 year before the study treatment
17. The subject has received phototherapy within 4 weeks before study treatment.
18. The subject has received live vaccine within 12 weeks before the study treatment.
19. The subject has presence of skin comorbidities that may interfere with study assessments.
20. The subject has known or suspected history of immunosuppression, including history of opportunistic infections (e.g., TB) per investigator's judgment.
21. The subject has active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit.
Note: Patients may be rescreened after infection resolves.
22. The subject has history of malignancy within 5 years before the screening period, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.
23. The subject planned or anticipated use of any prohibited medications and procedures during study treatment.
24. The subject planned or anticipated major surgical procedure during the patient's participation in this study.
25. High risk of parasite infection
Evidence of parasitic infection defined as having the following two items:
25.1 Risk factors for parasitic disease (living in an endemic area, chronic gastrointestinal symptoms, travel within the last 6 months to regions where geohelminthic infections are endemic, and/or chronic immunosuppression) AND 25.2 Evidence of parasitic colonization or infection on stool evaluation for ova and parasites.
Note: stool ova and parasite evaluation will only be conducted in patients with risk factors and an eosinophil count more than twice the upper limit of normal
26. Judged by investigator due to non-compliance with the study requirement or severe concomitant illness.
2. The subject has a positive test result for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C virus antibody, or human immunodeficiency virus antibodies at screening. Having a history of human immunodeficiency virus (HIV) infection.
3. The subject has a history of drug abuse that would impair or risk the patients' full participation in the study, in the opinion of the investigator.
4. The subject has a clinically significant, currently active or underlying gastrointestinal, cardiovascular, nervous system, psychiatric, metabolic, renal, hepatic, respiratory (with the exception of uncomplicated allergic rhinitis), inflammatory, immunological, endocrine, diabetes, or infectious disease and is ineligible to participate in the study as judged by the investigator.
5. The subject has a clinically significant history, as determined by the investigator, of drug allergies or hypersensitivity such as, but not limited to, sulfonamides and penicillin, or a drug allergy witnessed in a previous study with experimental drugs.
6. The subject has any history of a previous anaphylactic reaction.
7. The subject has any condition that, in the opinion of the investigator, would compromise the study or the well-being of the subject or prevent the subject from meeting or performing study requirements.
8. The subject has received TCS or TCI within 7 days before the baseline visit (Day 1).
9. The subject has received any immunoglobulin products or blood products within 3 months of baseline visit (Day 1).
10. The subject has received a biologic product (including investigational biologic product):
10.1 Any cell-depleting agents, not only limited to rituximab, within 6 months of baseline visit (Day 1), or before the lymphocyte count returns to normal, whichever is longer.
10.2 Other biologics such as dupilumab within 5 half-lives (if known) or within 16 weeks, whichever is longer, before the study treatment.
11. Initiation of treatment of AD with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period (patients may continue using stable doses of such moisturizers if initiated before the screening visit)
12. The subject has received an investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer, before study treatment.
13. The subject is a member of the professional or ancillary personnel involved in the study.
14. The subject regular use (≧2 visits per week) of a tanning booth/parlor within 4 weeks of the baseline visit (Day 1).
15. The subject has received any immunotherapy treatment within 3 months of baseline visit (Day 1).
16. The subject has used any of the following classes of medication (prescription or over the counter):
16.1 Systemic corticosteroids within 4 weeks before the study treatment 16.2 Leukotriene modifiers within 4 weeks before the study treatment 16.3 Cyclosporine within 12 weeks before the study treatment, or other immunosuppressants (e.g. gold salts, methotrexate, azathioprine) within 4 weeks before the study treatment 16.4 IFN-gamma within 12 weeks before the study treatment, or other immunomodulating drugs within 4 weeks before the study treatment 16.5 Anti-IgE (e.g., omalizumab) within 1 year before the study treatment 16.6 Allergen immunotherapy within 1 year before the study treatment
17. The subject has received phototherapy within 4 weeks before study treatment.
18. The subject has received live vaccine within 12 weeks before the study treatment.
19. The subject has presence of skin comorbidities that may interfere with study assessments.
20. The subject has known or suspected history of immunosuppression, including history of opportunistic infections (e.g., TB) per investigator's judgment.
21. The subject has active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit.
Note: Patients may be rescreened after infection resolves.
22. The subject has history of malignancy within 5 years before the screening period, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.
23. The subject planned or anticipated use of any prohibited medications and procedures during study treatment.
24. The subject planned or anticipated major surgical procedure during the patient's participation in this study.
25. High risk of parasite infection
Evidence of parasitic infection defined as having the following two items:
25.1 Risk factors for parasitic disease (living in an endemic area, chronic gastrointestinal symptoms, travel within the last 6 months to regions where geohelminthic infections are endemic, and/or chronic immunosuppression) AND 25.2 Evidence of parasitic colonization or infection on stool evaluation for ova and parasites.
Note: stool ova and parasite evaluation will only be conducted in patients with risk factors and an eosinophil count more than twice the upper limit of normal
26. Judged by investigator due to non-compliance with the study requirement or severe concomitant illness.
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oneness Biotech Co., Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
NienYi Chen, PhD
Role: PRINCIPAL_INVESTIGATOR
Oneness Biotech
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zenith Research
Beverly Hills, California, United States
Site Status
Encino Research Center
Encino, California, United States
Site Status
Marvel Research 002, LLC
Huntington Beach, California, United States
Site Status
Providence Clinical Research
North Hollywood, California, United States
Site Status
ACRC Studies
San Diego, California, United States
Site Status
Unison Clinical Trials
Sherman Oaks, California, United States
Site Status
University Clinical Research - Deland, LLC
DeLand, Florida, United States
Site Status
FXM Clinical Research Ft. Lauderdale, LLC.
Fort Lauderdale, Florida, United States
Site Status
Sweet Hope Research Specialty
Hialeah, Florida, United States
Site Status
Universal Axon - Homestead, LLC
Homestead, Florida, United States
Site Status
FXM Clinical Research Miramar, LLC
Miramar, Florida, United States
Site Status
FXM Clinical Research Miami, LLC
Miramar, Florida, United States
Site Status
Moore Clinical Research
Tampa, Florida, United States
Site Status
Avita Clinical Research (PCRS Network)
Tampa, Florida, United States
Site Status
Oakland Hills Dermatology (PCRS Network)
Auburn Hills, Michigan, United States
Site Status
Revival Research Institute, LLC
Troy, Michigan, United States
Site Status
Paddington Testing Co, Inc
Philadelphia, Pennsylvania, United States
Site Status
Clinical Research Partners
Richmond, Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FB825CLRS01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Sublingual Immunotherapy in Patients With Atopic Dermatitis
NCT01471119
COMPLETED
PHASE2
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
NCT04668066
COMPLETED
PHASE1
Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis
NCT00832585
COMPLETED
PHASE4
Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis
NCT06553209
COMPLETED
PHASE1
An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis
NCT03758716
COMPLETED
PHASE2
A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis
NCT04643457
COMPLETED
PHASE1/PHASE2
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07011706
RECRUITING
PHASE2
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
NCT07150845
RECRUITING
PHASE2
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
NCT03568162
COMPLETED
PHASE2
A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated
NCT03822832
COMPLETED
PHASE2
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
NCT07205081
RECRUITING
PHASE1
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis
NCT01756898
COMPLETED
PHASE2
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
NCT04212169
COMPLETED
PHASE2
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
NCT06790121
ACTIVE_NOT_RECRUITING
PHASE2
Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis
NCT03091426
COMPLETED
PHASE2
Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis
NCT04992546
COMPLETED
PHASE2
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
NCT00125333
COMPLETED
PHASE1/PHASE2
Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis
NCT02087943
COMPLETED
PHASE2
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
NCT05186922
UNKNOWN
PHASE1/PHASE2
A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis
NCT00703573
COMPLETED
PHASE2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis
NCT06248814
COMPLETED
PHASE1
A First-in-Human Study of QY211 Gel in Adult Subjects
NCT05843422
UNKNOWN
PHASE1
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
NCT06931990
NOT_YET_RECRUITING
PHASE1/PHASE2
A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis
NCT04256174
COMPLETED
PHASE1
Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
NCT06239311
RECRUITING
PHASE3